Robyn P.M. Saw

66.6k total citations · 2 hit papers
178 papers, 5.1k citations indexed

About

Robyn P.M. Saw is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, Robyn P.M. Saw has authored 178 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 162 papers in Oncology, 63 papers in Molecular Biology and 30 papers in Epidemiology. Recurrent topics in Robyn P.M. Saw's work include Cutaneous Melanoma Detection and Management (121 papers), Melanoma and MAPK Pathways (51 papers) and CAR-T cell therapy research (46 papers). Robyn P.M. Saw is often cited by papers focused on Cutaneous Melanoma Detection and Management (121 papers), Melanoma and MAPK Pathways (51 papers) and CAR-T cell therapy research (46 papers). Robyn P.M. Saw collaborates with scholars based in Australia, Netherlands and United States. Robyn P.M. Saw's co-authors include John F. Thompson, Richard A. Scolyer, Georgina V. Long, Alexander M. Menzies, Jonathan R. Stretch, Andrew J. Spillane, Kerwin F. Shannon, Matteo S. Carlino, Rajmohan Murali and Richard Kefford and has published in prestigious journals such as Nature Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Robyn P.M. Saw

166 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma

2012 606 citations Richard A. Scolyer, Marc Moncrieff et al. Journal of Clinical Oncology profile →
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

2014 382 citations Helen Rizos, Alexander M. Menzies et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Robyn P.M. Saw

Since Specialization

Citations

This map shows the geographic impact of Robyn P.M. Saw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robyn P.M. Saw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robyn P.M. Saw more than expected).

Fields of papers citing papers by Robyn P.M. Saw

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robyn P.M. Saw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robyn P.M. Saw. The network helps show where Robyn P.M. Saw may publish in the future.

Co-authorship network of co-authors of Robyn P.M. Saw

This figure shows the co-authorship network connecting the top 25 collaborators of Robyn P.M. Saw. A scholar is included among the top collaborators of Robyn P.M. Saw based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robyn P.M. Saw. Robyn P.M. Saw is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Nodal radioactivity after lymphoscintigraphy as a guide to sentinel node–positivity in melanoma patients 2025 ·European Journal of Surgical Oncology ·John F. Thompson, Roger F. Uren, Kevin London, David Chung, Robyn P.M. Saw, Andrew J. Spillane, (unknown), Kerwin F. Shannon, Julie R. Howle, Omgo E. Nieweg, Sydney Ch’ng, Thomas E. Pennington, Alison J. Potter, Richard A. Scolyer, Gabrielle Williams	0
2	Leg Lymphoedema After Inguinal and Ilio-Inguinal Lymphadenectomy for Melanoma: Results from a Prospective, Randomised Trial 2024 ·Annals of Surgical Oncology ·T. S. Lee, (unknown), Barbara Perić, Robyn P.M. Saw, João Pedreira Duprat Neto, Eduardo Bertolli, John Spillane, Barbara L. van Leeuwen, Marc Moncrieff, Antonio Sommariva, (unknown), Johannes H.W. de Wilt, (unknown), Jenny L. C. Geh, Julie R. Howle, Andrew J. Spillane	1
3	FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma. 2024 ·Journal of Clinical Oncology ·Li Zhou, Edward Hsiao, Serigne Lo, Matteo S. Carlino, George Au‐Yeung, Maria Gonzalez, Andrew J. Spillane, Thomas E. Pennington, Julie R. Howle, Kerwin F. Shannon, Rony Kapoor, Jonathan R. Stretch, David Gyorki, Robyn P.M. Saw, Sydney Ch’ng, Richard A. Scolyer, Georgina V. Long, Alexander M. Menzies	0
4	Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial. 2024 ·Journal of Clinical Oncology ·Christian U. Blank, (unknown), Richard A. Scolyer, Bart A. van de Wiel, Alexander M. Menzies, Marta López‐Yurda, Alexander Christopher Jonathan Van Akkooi, Winan J. van Houdt, Robyn P.M. Saw, (unknown), Serigne Lo, Geke A.P. Hospers, Matteo S. Carlino, Jan Willem de Groot, Ellen Kapiteijn, Karijn P.M. Suijkerbuijk, Piotr Rutkowski, Shahneen Sandhu, (unknown), Georgina V. Long	9
5	Quality of life with neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) versus adjuvant nivolumab in resectable stage III melanoma: 36-week data from the phase 3 NADINA trial. 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), Alexander M. Menzies, (unknown), Robyn P.M. Saw, Winan J. van Houdt, Mark B. Faries, Caroline Robert, Paolo A. Ascierto, Célèste Lebbé, Matteo S. Carlino, Ellen Kapiteijn, Karijn P.M. Suijkerbuijk, Piotr Rutkowski, Shahneen Sandhu, (unknown), Georgina V. Long, Christian U. Blank, Lonneke V. van de Poll‐Franse, J. Lijnsvelt	0
6	Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma 2024 ·Annals of Oncology ·Alexander M. Menzies, Serigne Lo, Robyn P.M. Saw, Maria Gonzalez, Sydney Ch’ng, (unknown), Kerwin F. Shannon, (unknown), Jenny Lee, Louise Emmett, (unknown), (unknown), Jonathan R. Stretch, John F. Thompson, (unknown), Helen Rizos, (unknown), Georgina V. Long	8
7	1095P Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma 2023 ·Annals of Oncology ·Irene L. M. Reijers, Petros Dimitriadis, Alexander M. Menzies, Ellen Kapiteijn, Astrid A.M. van der Veldt, Karijn P.M. Suijkerbuijk, Geke A.P. Hospers, Winan J. van Houdt, Robyn P.M. Saw, Annegien Broeks, Sten Cornelissen, Lindsay G. Grijpink-Ongering, Thomas E. Pennington, Andrew J. Colebatch, B. van de Wiel, Richard A. Scolyer, Alexander C. J. van Akkooi, Georgina V. Long, Christian U. Blank	2
8	Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach 2023 ·Journal of Translational Medicine ·(unknown), Tuba N. Gide, Nurudeen A. Adegoke, Camelia Quek, (unknown), Alison J. Potter, Ellis Patrick, Robyn P.M. Saw, John F. Thompson, Andrew J. Spillane, Kerwin F. Shannon, Matteo S. Carlino, Serigne Lo, Alexander M. Menzies, Inês Pires da Silva, Georgina V. Long, Richard A. Scolyer, James S. Wilmott	6
9	The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo. 2023 ·Journal of Clinical Oncology ·Irene L. M. Reijers, Alexander M. Menzies, Judith M. Versluis, Robyn P.M. Saw, Winan J. van Houdt, Ellen Kapiteijn, (unknown), Karijn P.M. Suijkerbuijk, Hanna Eriksson, Geke A.P. Hospers, W. Martin C. Klop, Marta López‐Yurda, Lindsay G. Grijpink-Ongering, Maria Gonzalez, Andrew J. Spillane, Richard A. Scolyer, Bart A. van de Wiel, Alexander Christopher Jonathan Van Akkooi, Georgina V. Long, Christian U. Blank	6
10	A systematic review with evidence mapping of supportive care interventions for melanoma patients and caregivers 2023 ·Cancer Medicine ·(unknown), Rehana A Salam, (unknown), Mbathio Dieng, Robyn P.M. Saw, (unknown)	3
11	Successful Manufacturing of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy from Cryopreserved Melanoma Tumors Shipped from Australia 2022 ·Transplantation and Cellular Therapy ·(unknown), Adrian Wells, (unknown), (unknown), Georgina V. Long, Richard A. Scolyer, Rebecca Velickovic, Robyn P.M. Saw, Thomas E. Pennington, Alexander M. Menzies, Madan Jagasia, Arvind Natarajan, (unknown)	1
12	Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA 2022 ·Frontiers in Oncology ·Russell J. Diefenbach, Jenny Lee, Ashleigh Stewart, Alexander M. Menzies, Matteo S. Carlino, Robyn P.M. Saw, Jonathan R. Stretch, Georgina V. Long, Richard A. Scolyer, Helen Rizos	1
13	Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition 2020 ·Nature Communications ·Jenny Lee, Elena Shklovskaya, Su Yin Lim, Matteo S. Carlino, Alexander M. Menzies, Ashleigh Stewart, Bernadette Pedersen, (unknown), Sara Alavi, Jean Yang, Dario Strbenac, Robyn P.M. Saw, John F. Thompson, James S. Wilmott, Richard A. Scolyer, Georgina V. Long, Richard Kefford, Helen Rizos	193
14	Clinical outcomes following surgical treatment of lentigo maligna of the head and neck 2020 ·European Journal of Surgical Oncology ·Gareth Crouch, (unknown), Serigne Lo, Robyn P.M. Saw, KK Lee, Jonathan R. Stretch, Kerwin F. Shannon, Pascale Guitera, Richard A. Scolyer, John F. Thompson, Sydney Ch’ng	9
15	Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials 2019 ·Clinical Cancer Research ·Jarem Edwards, Annie Tasker, Inês Pires da Silva, Camelia Quek, Marcel Batten, Angela L. Ferguson, (unknown), (unknown), Robyn P.M. Saw, John F. Thompson, Alexander M. Menzies, Umaimainthan Palendira, James S. Wilmott, Georgina V. Long, Richard A. Scolyer	26
16	CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment 2018 ·Clinical Cancer Research ·Jarem Edwards, James S. Wilmott, Jason Madore, Tuba N. Gide, Camelia Quek, Annie Tasker, Angela L. Ferguson, Jinbiao Chen, Rehana Hewavisenti, Peter Hersey, Thomas Gebhardt, Wolfgang Weninger, Warwick J. Britton, Robyn P.M. Saw, John F. Thompson, Alexander M. Menzies, Georgina V. Long, Richard A. Scolyer, Umaimainthan Palendira	317
17	Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma 2017 ·Clinical Cancer Research ·Ricardo E. Vilain, Alexander M. Menzies, James S. Wilmott, Hojabr Kakavand, Jason Madore, Alexander Guminski, Elizabeth Liniker, Benjamin Y. Kong, Adam Cooper, Julie R. Howle, Robyn P.M. Saw, Valerie Jakrot, Serigne Lo, John F. Thompson, Matteo S. Carlino, Richard Kefford, Georgina V. Long, Richard A. Scolyer	191
18	PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors 2017 ·Clinical Cancer Research ·Hojabr Kakavand, Robert V. Rawson, Gulietta M. Pupo, Jean Yang, Alexander M. Menzies, Matteo S. Carlino, Richard Kefford, Julie R. Howle, Robyn P.M. Saw, John F. Thompson, James S. Wilmott, Georgina V. Long, Richard A. Scolyer, Helen Rizos	63
19	BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact breakdown → 2014 ·Clinical Cancer Research ·Helen Rizos, Alexander M. Menzies, Gulietta M. Pupo, Matteo S. Carlino, Carina Fung, Jessica Hyman, Lauren E. Haydu, Branka Mijatov, Therese M. Becker, Suzanah C. Boyd, Julie R. Howle, Robyn P.M. Saw, John F. Thompson, Richard Kefford, Richard A. Scolyer, Georgina V. Long	382
20	Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma 2013 ·Molecular Cancer Therapeutics ·Matteo S. Carlino, Kavitha Gowrishankar, Catherine A.B. Saunders, Gulietta M. Pupo, (unknown), Xu Dong Zhang, Robyn P.M. Saw, Therese M. Becker, Richard Kefford, Georgina V. Long, Helen Rizos	61

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact